Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CRADA "Reasonable Price" Clause Becomes Part Of HHS Approps Bill

Executive Summary

"Reasonable" pricing for drugs developed with federal funding is closer to making a comeback with passage of an amendment to the fiscal 2001 Labor/HHS/ Education appropriations bill in the House.

You may also be interested in...



NIH Royalty Plan Due March 31 Under Wyden Amendment To Funding Bill

The National Institutes of Health would be directed to develop a plan to ensure a "reasonable rate of return" on taxpayer funded research under an amendment to the Senate Labor/HHS appropriations bill.

NIH Royalty Plan Due March 31 Under Wyden Amendment To Funding Bill

The National Institutes of Health would be directed to develop a plan to ensure a "reasonable rate of return" on taxpayer funded research under an amendment to the Senate Labor/HHS appropriations bill.

Jeffords Rx Re-Importation Bill Gains Sen. Gorton's Support

Sen. Jeffords' (R-Vt.) prescription drug re-importation bill has gained the support of another border-state Republican: Sen. Gorton of Washington.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS036196

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel